TLR3 and colorectal carcinoma: Building on prior evidence that the toll‐like receptor 3 (TLR3) agonist Poly(I:C) is an effective adjuvant for neoantigen‐peptide vaccines in digestive system immunotherapy,[27] we developed MSS‐CRC neoantigen vaccines (Neo‐CRCVAS) comprising seven neoantigen peptides (10 μg/peptide) combined with Poly(I:C) for further study.